Vitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma

May Cho, Parvin F. Peddi, Kevin Ding, Ling Chen, Denise Thomas, Jian Wang, Albert C. Lockhart, Benjamin Tan, Andrea Wang-Gillam

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: The prevalence of vitamin D deficiency among patients with cancer has been previously reported. Because vitamin D is fat soluble, patients with pancreatic adenocarcinoma may have an especially high risk of vitamin D deficiency in association with ongoing and varying degrees of malabsorption. However, little is known about the correlation between vitamin D status and prognosis in these patients.Methods: We conducted a retrospective review of vitamin D status in patients with pancreatic adenocarcinoma who were treated at Siteman Cancer Center. Patients' demographic information, clinical staging at the time of vitamin D assessment, vitamin D levels, and survival data were collected. Vitamin D deficiency was defined as a serum 25-hydroxyvitamin D (25[OH]D) level of less than 20 ng/mL, and vitamin D insufficiency was defined as a 25(OH)D level of between 20 ng/mL and 30 ng/mL.Results: Between December 2007 and June 2011, 178 patients with pancreatic adenocarcinoma had their vitamin D levels checked at the time of initial visit at this center. Of these 178 patients, 87 (49%) had vitamin D deficiency, and 44 (25%) had vitamin D insufficiency. The median 25(OH)D level was significantly lower among nonwhite patients and among patients with stage I and II disease. A 25(OH)D level of less than 20 ng/mL was found to be associated with poor prognosis (p = 0.0019) in patients with stage III and IV disease.Conclusions: Vitamin D insufficiency and deficiency were prevalent among patients with pancreatic adenocarcinoma. The vitamin D level appears to be prognostic for patients with advanced pancreatic adenocarcinoma, and its effects should be further examined in a prospective study.

Original languageEnglish (US)
Article number206
JournalJournal of Translational Medicine
Volume11
Issue number1
DOIs
StatePublished - Sep 8 2013
Externally publishedYes

Fingerprint

Vitamin D Deficiency
Vitamin D
Adenocarcinoma
Neoplasms
Fats
Demography

Keywords

  • Pancreatic cancer
  • Prognostic factors
  • Vitamin D
  • Vitamin D receptor

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Vitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma. / Cho, May; Peddi, Parvin F.; Ding, Kevin; Chen, Ling; Thomas, Denise; Wang, Jian; Lockhart, Albert C.; Tan, Benjamin; Wang-Gillam, Andrea.

In: Journal of Translational Medicine, Vol. 11, No. 1, 206, 08.09.2013.

Research output: Contribution to journalArticle

Cho, M, Peddi, PF, Ding, K, Chen, L, Thomas, D, Wang, J, Lockhart, AC, Tan, B & Wang-Gillam, A 2013, 'Vitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma', Journal of Translational Medicine, vol. 11, no. 1, 206. https://doi.org/10.1186/1479-5876-11-206
Cho, May ; Peddi, Parvin F. ; Ding, Kevin ; Chen, Ling ; Thomas, Denise ; Wang, Jian ; Lockhart, Albert C. ; Tan, Benjamin ; Wang-Gillam, Andrea. / Vitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma. In: Journal of Translational Medicine. 2013 ; Vol. 11, No. 1.
@article{5b51c76067df4de99d970de866011dd3,
title = "Vitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma",
abstract = "Background: The prevalence of vitamin D deficiency among patients with cancer has been previously reported. Because vitamin D is fat soluble, patients with pancreatic adenocarcinoma may have an especially high risk of vitamin D deficiency in association with ongoing and varying degrees of malabsorption. However, little is known about the correlation between vitamin D status and prognosis in these patients.Methods: We conducted a retrospective review of vitamin D status in patients with pancreatic adenocarcinoma who were treated at Siteman Cancer Center. Patients' demographic information, clinical staging at the time of vitamin D assessment, vitamin D levels, and survival data were collected. Vitamin D deficiency was defined as a serum 25-hydroxyvitamin D (25[OH]D) level of less than 20 ng/mL, and vitamin D insufficiency was defined as a 25(OH)D level of between 20 ng/mL and 30 ng/mL.Results: Between December 2007 and June 2011, 178 patients with pancreatic adenocarcinoma had their vitamin D levels checked at the time of initial visit at this center. Of these 178 patients, 87 (49{\%}) had vitamin D deficiency, and 44 (25{\%}) had vitamin D insufficiency. The median 25(OH)D level was significantly lower among nonwhite patients and among patients with stage I and II disease. A 25(OH)D level of less than 20 ng/mL was found to be associated with poor prognosis (p = 0.0019) in patients with stage III and IV disease.Conclusions: Vitamin D insufficiency and deficiency were prevalent among patients with pancreatic adenocarcinoma. The vitamin D level appears to be prognostic for patients with advanced pancreatic adenocarcinoma, and its effects should be further examined in a prospective study.",
keywords = "Pancreatic cancer, Prognostic factors, Vitamin D, Vitamin D receptor",
author = "May Cho and Peddi, {Parvin F.} and Kevin Ding and Ling Chen and Denise Thomas and Jian Wang and Lockhart, {Albert C.} and Benjamin Tan and Andrea Wang-Gillam",
year = "2013",
month = "9",
day = "8",
doi = "10.1186/1479-5876-11-206",
language = "English (US)",
volume = "11",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Vitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma

AU - Cho, May

AU - Peddi, Parvin F.

AU - Ding, Kevin

AU - Chen, Ling

AU - Thomas, Denise

AU - Wang, Jian

AU - Lockhart, Albert C.

AU - Tan, Benjamin

AU - Wang-Gillam, Andrea

PY - 2013/9/8

Y1 - 2013/9/8

N2 - Background: The prevalence of vitamin D deficiency among patients with cancer has been previously reported. Because vitamin D is fat soluble, patients with pancreatic adenocarcinoma may have an especially high risk of vitamin D deficiency in association with ongoing and varying degrees of malabsorption. However, little is known about the correlation between vitamin D status and prognosis in these patients.Methods: We conducted a retrospective review of vitamin D status in patients with pancreatic adenocarcinoma who were treated at Siteman Cancer Center. Patients' demographic information, clinical staging at the time of vitamin D assessment, vitamin D levels, and survival data were collected. Vitamin D deficiency was defined as a serum 25-hydroxyvitamin D (25[OH]D) level of less than 20 ng/mL, and vitamin D insufficiency was defined as a 25(OH)D level of between 20 ng/mL and 30 ng/mL.Results: Between December 2007 and June 2011, 178 patients with pancreatic adenocarcinoma had their vitamin D levels checked at the time of initial visit at this center. Of these 178 patients, 87 (49%) had vitamin D deficiency, and 44 (25%) had vitamin D insufficiency. The median 25(OH)D level was significantly lower among nonwhite patients and among patients with stage I and II disease. A 25(OH)D level of less than 20 ng/mL was found to be associated with poor prognosis (p = 0.0019) in patients with stage III and IV disease.Conclusions: Vitamin D insufficiency and deficiency were prevalent among patients with pancreatic adenocarcinoma. The vitamin D level appears to be prognostic for patients with advanced pancreatic adenocarcinoma, and its effects should be further examined in a prospective study.

AB - Background: The prevalence of vitamin D deficiency among patients with cancer has been previously reported. Because vitamin D is fat soluble, patients with pancreatic adenocarcinoma may have an especially high risk of vitamin D deficiency in association with ongoing and varying degrees of malabsorption. However, little is known about the correlation between vitamin D status and prognosis in these patients.Methods: We conducted a retrospective review of vitamin D status in patients with pancreatic adenocarcinoma who were treated at Siteman Cancer Center. Patients' demographic information, clinical staging at the time of vitamin D assessment, vitamin D levels, and survival data were collected. Vitamin D deficiency was defined as a serum 25-hydroxyvitamin D (25[OH]D) level of less than 20 ng/mL, and vitamin D insufficiency was defined as a 25(OH)D level of between 20 ng/mL and 30 ng/mL.Results: Between December 2007 and June 2011, 178 patients with pancreatic adenocarcinoma had their vitamin D levels checked at the time of initial visit at this center. Of these 178 patients, 87 (49%) had vitamin D deficiency, and 44 (25%) had vitamin D insufficiency. The median 25(OH)D level was significantly lower among nonwhite patients and among patients with stage I and II disease. A 25(OH)D level of less than 20 ng/mL was found to be associated with poor prognosis (p = 0.0019) in patients with stage III and IV disease.Conclusions: Vitamin D insufficiency and deficiency were prevalent among patients with pancreatic adenocarcinoma. The vitamin D level appears to be prognostic for patients with advanced pancreatic adenocarcinoma, and its effects should be further examined in a prospective study.

KW - Pancreatic cancer

KW - Prognostic factors

KW - Vitamin D

KW - Vitamin D receptor

UR - http://www.scopus.com/inward/record.url?scp=84883509784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883509784&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-11-206

DO - 10.1186/1479-5876-11-206

M3 - Article

VL - 11

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 206

ER -